Fern M. Anari, MD

Publications

• Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch Syndrome, metastatic colon and localized urothelial cancer. The Oncologist.
• Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Saltzberg PD, Bubes N, Anari F, Kasireddy V, Varshavsky A, Liu Y, Ross E, El-Deiry WS. Clinical use of liquid biopsies to detect actionable driver mutations, guide treatment decisions and monitor disease burden during treatment of 33 metastatic colorectal cancer patients at Fox Chase Cancer Center GI Oncology subspecialty clinic. Frontiers in Oncology. 2019 Jan, 8(1-8).    
• Anari F, Dotan E. Management of Older Adults with Colorectal Cancer. Hospital Physician Hematology/Oncology Board Review Manual. 2018,13(4):7-22. 
• Anari F, Ramamurthy C, Zibelman M. Impact of Tumor Microenvironment Composition on Therapeutic Responses and Clinical Outcomes in cancer. Future Oncology. 2018 Jun;14(14):1409-1421.
• Anari F, O’Neill J, Choi W, Chen D, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg R, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas C, Trabulsi E, Smaldone M, Geynisman D, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER. Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology. 2018 May;1(1):54-60.